BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 25, 2025
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

In the clinic for Jan. 7, 2021

Jan. 7, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Aldeyra, Alnylam, AM-Pharma, Basilea, Pfizer, Pharmaessentia.
Read More
Respiratory infection

Nextgen launches trial for rapid breath test to measure COVID-19 vaccine efficacy

Jan. 6, 2021
By Annette Boyle
Nextgen Biomed Ltd. has begun a clinical trial of a breath test to monitor antibody levels in individuals vaccinated against COVID-19. Be'er Ya'akov, Israel-based Shamir Medical Center authorized the trial for test developer Scent Medical Technologies Ltd. (Scentech Medical), which is in the midst of merging with Nextgen. The merged company will be called Scentech Medical.
Read More
Digital illustration of U.S., coronavirus

Stenzel: FDA not in a hurry to address EUA conversion due to persistence of pandemic

Jan. 6, 2021
By Mark McCarty
The U.S. FDA is actively working on guidance for conversion of emergency use authorizations (EUAs) to conventional premarket review programs, but the FDA’s Tim Stenzel said he does “not perceive a need to rush to convert EUAs” because of the volume of EUA applications, and because he does not expect the public health emergency “to end anytime soon.”
Read More

Regulatory front for Jan. 6, 2021

Jan. 6, 2021
By Mark McCarty
The latest global regulatory news, changes and updates affecting medical devices and technologies, including: FDA grants EUA to Quanterix for Simoa test; EC investing in startups; Alternatives to animal testing a challenge; USPTO seeks more uniformity between PTAB, courts; NICE nods to Olympus Plasma for BPH.
Read More

Other news to note for Jan. 6, 2021

Jan. 6, 2021
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Advanced Oncotherapy, Apex Family Medical, Bioclinica, Biodesix, Bio-Techne, Biotheranostics, Bioventrix, Carmat, Change Healthcare, Cssi Lifesciences, Diamedcare, Fathom Consulting, Fresenius Kabi, Helix Opco, Helius Medical Technologies, Hologic, Illumina, Medacuity, Monteris Medical, Nephros, Novasep, Optimuminsight, Pointclickcare, Rewalk Robotics, Saliency, Sartorius, Scaleready, Seegene, Sequans Communications, Skylight Health, Tonic Bioventures, Withings, Valgenesis.
Read More

Moderna’s COVID-19 vaccine second to clear EMA approval

Jan. 6, 2021
By Nuala Moran
LONDON – The EMA has recommended approval of Moderna Inc.’s COVID-19 vaccine, becoming the fourth western regulator to do so, after Israel approved the product on Jan. 5 and the FDA and Health Canada in December.
Read More

Regulatory actions for Jan. 6, 2021

Jan. 6, 2021
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amolyt, Astellas, Astrazeneca, Everest, Inventiva, Moderna, RDIF, Redhill, Stealth.
Read More

Other news to note for Jan. 6, 2021

Jan. 6, 2021
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aerpio, Aikido, Aim Immunotech, Ana, Asana, ASN, Autolus, Avicanna, Benuvia, Bold, Brickbio, Cristal, Dewpoint, Erasca, Gilead, Intravacc, Iovaxis, Kite, Millendo, Mindset, Neurobo, Nikang, Oxford Biotherapeutics, Pfizer, Radius, Respirex, RDIF, Selecta, Servier, Silo, Targovax, Vaxcyte, Vistagen X-Chem.
Read More

In the clinic for Jan. 6, 2021

Jan. 6, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Creative Medical, Erasca, Imara, Infinity, Inovio, Millendo, Mycovia, Ocuphire, Regenxbio, Seres, Vir, Windtree, Zentalis.
Read More
Vaccine administration

Change to COVID-19 vaccine dosing schedule stirs debate

Jan. 5, 2021
By Nuala Moran
LONDON – Controversy has erupted over COVID-19 vaccines dosing after the U.K. said it is to prioritize giving as many people as possible a single dose of the two currently approved products, rather than two doses three or four weeks apart, as scheduled on their labels. The move prompted a sharp rebuke from FDA Commissioner Stephen Hahn and Peter Marks, director of FDA’s Center for Biologics Evaluation, who said any such change “is not rooted in the science.”
Read More
Previous 1 2 … 304 305 306 307 308 309 310 311 312 … 551 552 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing